Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion type Assertion NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_head.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_provenance.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion evidence source_evidence_literature NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_provenance.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion SIO_000772 16507781 NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_provenance.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion wasDerivedFrom befree-20140225 NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_provenance.
- NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_assertion wasGeneratedBy ECO_0000203 NP448200.RAkLZu-wNrwMGaeJmVTNGWhwwAHqtai3_SrakoY0MGj6g130_provenance.